
Localisation of the molecular chaperone site of 14-3-3 ζ ; an intracellular protein associated with toxic neurological protein aggregates

Katy Louise Goodwin

School of Physical Sciences

The University of Adelaide

Supervised by Prof. John A. Carver

and Dr Joanna M. Woodcock

This thesis is submitted to The University of Adelaide

for the degree of *Doctor of Philosophy*.

February, 2015



THE UNIVERSITY
of ADELAIDE



Abstract

14-3-3 proteins are a family of acidic, dimeric, phospho-serine binding proteins, which are ubiquitously expressed in all mammals. There are 7 known isoforms in mammals (β , γ , ϵ , ζ , η , τ , σ), which have similar structures and roles. 14-3-3 proteins interact with over 200 target proteins and regulate many roles including apoptosis, protein transportation, mitosis and signal transduction. Due to these diverse roles, 14-3-3 proteins are associated with many diseases, e.g. cancer and neurodegenerative diseases. 14-3-3 is co-located with many neurological protein aggregates; however the role of 14-3-3 in these diseases is unknown. Recently the molecular chaperone action of 14-3-3 ζ was described whereby 14-3-3 ζ is able to interact with and stabilise aggregating target proteins.

Previous investigations into the regions responsible for chaperone action showed that the C-terminal extension and the polar face of the amphipathic binding groove of 14-3-3 ζ are unlikely to be involved in chaperone action. Here, the investigation into the site and mechanism of the molecular chaperone action is extended to target two major hydrophobic regions of 14-3-3 ζ : the hydrophobic face of the amphipathic binding groove and the dimer interface.

The hydrophobic face of the amphipathic binding groove is not a critical region for the chaperone action of 14-3-3 ζ . This was determined by the mutations of exposed hydrophobic residues, V176, L216, L220 and L227 and assessing the chaperone ability of these proteins compared with WT 14-3-3 ζ proteins against the amorphous aggregation of alcohol dehydrogenase and reduced insulin.

The dimer interface was determined to be involved in the chaperone activity of 14-3-3 ζ . This region was investigated by targeting hypothesised salt bridging sites in the dimer interface (D21 and E89). Disruption of this region can also be achieved via phosphorylation of S58. The 14-3-3 ζ protein, S58D, is a phospho-mimic which exhibits a similar dimer disruption. The disruption caused by these mutations was assessed and the chaperone ability was tested

against amorphous aggregation of alcohol dehydrogenase and reduced insulin and compared to WT 14-3-3 ζ . These dimer disrupted proteins exhibited enhanced chaperone ability, implying exposure of the dimer interface is important for the chaperone action of 14-3-3 ζ . In addition these 14-3-3 ζ mutants also exhibited a shift in the monomer-dimer equilibrium which results in the increased production of monomeric 14-3-3 ζ . This shift in the monomer-dimer equilibrium correlates with the enhanced chaperone ability of 14-3-3 ζ , suggestive of the 14-3-3 ζ monomer being an important chaperone active unit.

To further the investigation of the role of the dimer interface in the chaperone action of 14-3-3 ζ the interaction with a physiological lipid mimic was undertaken. The physiological lipid, sphingosine, is known to interact with 14-3-3 and cause disruption to the dimer interface in order to allow phosphorylation of S58. The interaction with a sphingosine mimic caused disruption to the dimer, and the chaperone ability in the presence of this mimic was assessed. There no observed effect on the chaperone activity of 14-3-3 ζ as a result of this interaction. However the disruption caused by this interaction is minor and may not be sufficient to cause enough disruption to expose significant region of the dimer interface required for enhanced chaperone ability.

Small angle scattering studies confirmed that the dimer interface is involved in the chaperone action of 14-3-3 ζ . Modelling the interaction between aggregating ADH and 14-3-3 ζ revealed that ADH interacts with dimeric 14-3-3 ζ via a region of the dimer interface. This allows the formation of the dimeric structure which maintains the stability of the ADH-14-3-3 complex. The independent movement of the two interaction regions of the dimer interface makes it possible for one side of the dimer interface to dissociate allowing the interaction with the aggregating target protein. The interactions on the other side of the dimer interface remain intact allowing the dimer to be maintained. This maintains the stability that comes with the dimeric form of 14-3-3 ζ whilst still allowing the interaction with aggregating protein via the hydrophobic dimer interface.

This investigation of the chaperone activity of 14-3-3 ζ has revealed that 14-3-3 acts as a molecular chaperone via the dimer interface. This interaction occurs when half of the dimer interface dissociates to allow access to amorphously aggregating target proteins. This allows the other side of the dimer interface to maintain salt bridging interactions and retain the dimeric state of the 14-3-3 ζ protein with the associated stability. This investigation is the first

instance in which a chaperone protein has been modelled interacting with an aggregating target protein. It also opens up the role of the dimer interface in 14-3-3 function, and clarifies that the monomeric 14-3-3 unit is unlikely to have a role in 14-3-3 pathology due to its inherent reduced stability.

This thesis has provided more in depth knowledge about the chaperone capability of 14-3-3 ζ and the potential role of 14-3-3 ζ in neurodegenerative disease. The precise function of 14-3-3 proteins in these diseases is not well understood, with 14-3-3 acting as both positive and negative regulator of protein aggregation. The determination of the mechanism of chaperone function of 14-3-3 ζ provides important information which can be utilised to further investigate the role of 14-3-3 in these diseases, leading to the development of new therapeutic techniques to overcome these debilitating diseases.

Declaration

Part of the written work in Chapter 1, was written as part of my honours year at the University of Adelaide. With the exception of this, I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

The small molecule, 41.14, was provided by Dr Joanna Woodcock and the phosphorylation investigations in chapter 6 were undertaken by Carl Coolen. The analysis of data obtained via small angle neutron scattering (chapter 7) was undertaken in collaboration with Dr Agata Rekas (National Deuteration Facility, ANSTO).

Katy Louise Goodwin

Date:

Acknowledgements

“We are so often caught up in our destination that we forget to appreciate the journey, especially the goodness of the people we meet along the way....”

~Unknown

Where else could I start but with thanking my wonderful supervisors, John and Jo. I recently realised how lucky I am to have two supervisors from different disciplines play such active roles in my PhD. I really think that it really rounded out my skills and allowed me insights into both the biological and chemical worlds.

To John, thank you for the guidance and sharing your expertise in such a friendly and welcoming manner. I will always treasure my time being a part of your research group.

To Jo, your enthusiasm about 14-3-3 proteins is so infectious and you make any lab a good place to work. I really don't think I would have made it through the past year without your faith, encouragement and understanding. I will always be grateful for the never-ending support!

To Agata, I can't thank you enough for your help and support whilst undertaking the scattering experiments and analysis. It is not only your help and guidance, but your friendly face that made my visits to ANSTO so memorable.

Many thanks to the Carver group, mainly, Kegg, Yanqin, Nick, Denise, Ran, Manjeet, Danielle and Dave. Thanks for all the laughs and support. You guys have made the lab a fun place to be over the years.

What is science without collaboration, and I have been lucky to work with many different people from around the country. Thank you to Matt Perugini for your time and allowing me to visit your lab to undertake the AUC experiments; Robert Knott and Katy Wood for your technical support whilst undertaking scattering experiments at ANSTO; Emma Parkinson-Lawrence, for getting me set up with the CD; Stephen Polyak, for always being willing to

help with a variety of protein issues; Paul Moretti, for imparting your DNA and site-directed mutagenesis knowledge; and Carl Coolen, for your aid with the phosphorylation work, always with a smile.

Many thanks to my wonderful family and friends for your endless support, understanding and patience over the past few years. You provided a fun place outside of the lab to spend my time, and I appreciate having you all in my life. Mum, I know it's your job, but thanks for listening to all my complaints with a cup of tea and a sympathetic ear. And Dad, you'll be pleased to know I have finished my "book" now.

Finally to Matt..... So many things have changed since I started my PhD, but you have always remained by my side. I could not have asked for a more supportive and awesome partner. I'm really looking forward to sharing many more adventures together.

Table of Contents

Abstract.....	i
Declaration.....	iv
Acknowledgements	v
Table of Contents	vii
List of figures.....	xiii
List of tables.....	xxi
Chapter 1: Introduction	1
1.1 14-3-3 Proteins.....	1
1.1.1 Roles of 14-3-3 proteins <i>in vivo</i>	3
1.1.2 Structural organisation of 14-3-3 proteins.....	7
1.1.3 14-3-3 proteins in disease.....	11
1.2 Protein Folding and Misfolding.....	13
1.2.1 Protein misfolding diseases	15
1.3 Molecular Chaperones	17
1.3.1 14-3-3 ζ as a molecular chaperone	19
1.4 Aims:.....	20
Chapter 2: Materials and Methods	22
2.1 Materials	22
2.2 Expression and purification of 14-3-3 proteins	23

2.2.1 14-3-3 Vectors	23
2.2.2 Generation of 14-3-3 constructs	23
2.2.3 Expression of TEVP and 14-3-3 proteins.....	23
2.2.4 Purification of TEVP	25
2.2.5 Purification of 14-3-3 proteins	25
2.2.6 Protein concentration determination	25
2.3 Biophysical Characterisation techniques	27
2.3.1 Intrinsic tryptophan fluorescence and thermostability of 14-3-3 ζ	27
2.3.2 Bis ANS assays	27
2.3.3 Far UV circular dichroism.....	27
2.3.4 Cross-linking of 14-3-3 ζ proteins with glutaraldehyde.....	28
2.3.5 Phosphorylation assays.....	28
2.3.6 Analytical ultracentrifugation.....	28
2.3.7 Experiments undertaken in the presence of sphingosine mimic #41.14	29
2.4 Chaperone assays	30
2.4.1 Chaperone Assays by light scattering	30
2.4.2 Chaperone assays by intrinsic tryptophan fluorescence.....	30
2.4.3 Chaperone activity in the presence of 41.14	30
2.4.4 Determining the % protections provided by chaperones.....	31
2.5 Small angle scattering Techniques	32
2.5.1 Sample Preparation.....	32
2.5.2 Small angle X-ray Scattering	32

2.5.3 Small angle neutron scattering	32
Chapter 3: Investigation into the functional role of the hydrophobic face of the amphipathic binding groove of 14-3-3ζ.....	34
3.1 Introduction:.....	34
3.2 Results: Biophysical characterisation of the 14-3-3 proteins (WT, V176D and L216, 220, 227D)	37
3.2.1 Native PAGE analysis	37
3.2.2 Far UV Circular Dichroism	38
3.2.3 Intrinsic tryptophan fluorescence	40
3.2.4 Thermostability, monitored via intrinsic tryptophan fluorescence	42
3.3 Results: The role of the hydrophobic face of the amphipathic binding groove in the chaperone activity of 14-3-3	44
3.3.1 Reduction induced amorphous aggregation of insulin	44
3.3.2 Chemically stressed amorphous aggregation of alcohol dehydrogenase	46
3.3 Discussion.....	48
Chapter 4: An investigation into the functional role of the dimer interface of 14-3-3ζ in chaperone action	52
4.1 Introduction.....	52
4.2 Characterisation of dimer-disrupted 14-3-3 ζ proteins	55
4.2.1 Native PAGE analysis	55
4.2.2 Far-UV circular dichroism	56
4.2.3 Intrinsic tryptophan fluorescence	58
4.2.4 Thermostability monitored via intrinsic tryptophan fluorescence	64

4.2.5 Bis-ANS binding	66
4.2.6 Phosphorylation Assays	69
4.3 The role of the dimer interface in the chaperone action of 14-3-3 ζ	71
4.3.1 Chaperone action of dimer disrupted 14-3-3 ζ proteins against the amorphous aggregation of alcohol dehydrogenase monitored by light scattering.....	71
4.3.2 Chaperone action of dimer-disrupted proteins against the amorphous aggregation of reduced insulin as monitored by light scattering at 340nm.....	75
4.3.3 Chaperone action of dimer disrupted 14-3-3 ζ proteins against amorphous aggregation of reduced insulin monitored by fluorescence.....	77
4.4 Discussion.....	80
Chapter 5: Characterisation of the dimer-monomer equilibrium of 14-3-3ζ, by cross-linking and analytical ultracentrifugation.....	84
5.1 Introduction.....	84
5.2 Results: The monomer-dimer equilibrium of the dimer disrupted 14-3-3 ζ mutant proteins.....	86
5.2.1 Cross-linking with Glutaraldehyde	86
5.2.2 Analytical Ultracentrifugation.....	89
5.3 Discussion.....	97
Chapter 6: A structural and functional investigation into the chaperone ability of 14-3-3ζ in the presence of physiological lipid mimetics.....	100
6.1 Introduction.....	100
6.2 Results: Characterisation of the interaction between 14-3-3 ζ and sphingosine mimic, 41.14.	102
6.2.1 Phosphorylation assays.....	102

6.2.2 Intrinsic fluorescence of WT 14-3-3 ζ in the presence of 41.14	103
6.2.3 Thermostability of 14-3-3 ζ in the presence of 41.14	105
6.2.4 The binding of bis-ANS to WT 14-3-3 ζ in the presence of 41.14	106
6.3 Chaperone action of WT 14-3-3 ζ in the presence of sphingosine mimetics	109
6.4 Discussion.....	111
Chapter 7: The characterisation of the molecular chaperone action of 14-3-3ζ by small angle scattering techniques	114
7.1 Introduction.....	114
7.2 Results: Determination of the best conditions for scattering experiments	118
7.3 Results: Small angle x-ray scattering.....	120
7.4 Results: Small angle neutron scattering.....	125
7.4.1 Biophysical characterisation and chaperone activity assays of deuterated 14-3-3 ζ	125
7.4.2 Small angle neutron scattering of native 14-3-3 ζ and ADH	128
7.4.4 Monitoring the interaction between aggregating ADH and 14-3-3 ζ by SANS	134
7.5 Discussion.....	141
Chapter 8: Conclusions and Future Directions.....	147
8.1 Conclusions.....	148
8.2 Future Directions	153
Appendix A: Biophysical techniques.....	157
A.1 Far UV Circular Dichroism Spectroscopy	157
A.2 Intrinsic tryptophan fluorescence.....	158

A.3 Bis-ANS.....	161
Appendix B: Purity of WT 14-3-3ζ.....	163
References:.....	164

List of figures

- Figure 1.1:** Crystal structures of the seven human isoforms of the 14-3-3 dimer when bound to phospho-peptides (yellow); the phospho-peptides are bound in the amphipathic binding groove of the 14-3-3 monomer (taken from (1)). 1
- Figure 1.2:** The role of 14-3-3 in protection against apoptosis, whereby the phosphorylation of Bad results in binding to 14-3-3 leading to cell survival. This binding of Bad to 14-3-3 prevents its interaction with Bcl-2/X_L, an interaction which leads to apoptosis (taken from (10))..... 3
- Figure 1.3:** The phosphorylation of Raf-1 leads to the binding of 14-3-3, maintaining the inactive form of Raf-1. Upon activation of Ras, Raf-1 is sequestered to the plasma membrane, where 14-3-3 dissociates and allows Raf-1 to adopt its active state. 14-3-3 can bind to this active form to maintain this conformation. The activation of Raf-1 leads to the stimulation of further mechanisms that lead to cell proliferation (taken from (10))..... 4
- Figure 1.4:** When exposed to DNA damage, Cdc25 becomes phosphorylated which leads to the interaction with 14-3-3. This results in Cdc25 being retained in the cytoplasm and prevents its interaction with Cdc2/X_L, preventing the initiation of mitosis. An additional mitosis prevention mechanism is the sequestration of phosphorylation of Cdc2 into the cytoplasm by 14-3-3 σ (taken from (10)). 5
- Figure 1.5:** The crystal structure of the 14-3-3 ζ dimer highlighting the amphipathic binding groove. The individual monomers coloured (red and blue) and the nine alpha helices are numbered. H3, H5, H7 and H9 encompass the amphipathic binding groove (16). 7
- Figure 1.6:** The crystal structure of the 14-3-3 ζ dimer, aligned to show the nature of the close interaction between the monomers (i.e. the dimer interface) via helices 1, 3 and 4 to form the dimeric structure. 8

Figure 1.7: The 14-3-3 ζ monomer showing the flexible, acidic and unstructured C-terminal extension. The actual position of the C-terminal extension is not defined due to its dynamic nature (taken from (25)).	9
Figure 1.8: The aligned 14-3-3 C-terminal extensions of the seven human isoforms, with the conserved, acidic residues indicated in bold.	10
Figure 1.9: The folding of proteins into the native functional state occurs via the production of intermediately folded species on the on-folding pathway in a fast and reversible manner.	13
Figure 1.10: (A) The standard nucleation dependent mechanism for amyloid fibril formation starting with the formation of partially folded proteins (taken from (34)). (B) A model of an insulin protofilament, with four individual strands and the arrangement of β -sheets to form the amyloid fibril core (taken from (38)).	14
Figure 1.11: A schematic mechanism of the action of the small heat-shock proteins, showing the dissociation of the chaperone active unit from the chaperone oligomer.	18
Figure 3.1: The crystal structure of 14-3-3 ζ dimer showing the location of the selected hydrophobic residues, V176 (helix 7), L216, L220 and L227 (helix 9).	35
Figure 3.2: Native PAGE analysis of the generated 14-3-3 ζ proteins (WT, V176D and L216, 220, 227D) as single bands visualised using Coomassie staining.	37
Figure 3.3: The far-UV circular dichroism spectra comparing the WT 14-3-3 ζ (7.2 μ M) profile with that of V176D (A) and L216, 220, 227D (B) 14-3-3 ζ (7.2 μ M) between the wavelengths of 190 and 260nm.	39
Figure 3.4: The intrinsic fluorescence spectra of WT 14-3-3 ζ compared with V176D 14-3-3 ζ (A) and L216, 220, 227D 14-3-3 ζ (B).	41
Figure 3.5: The thermostability profiles of WT 14-3-3 ζ compared with (A) V176D 14-3-3 ζ and (B) L216, 220, 227D 14-3-3 ζ with increased temperature	43
Figure 3.6: The chaperone activity of (A) WT, (B) V176D and (C) L216, 220, 227D 14-3-3 ζ against the amorphous aggregation of reduced insulin in 20mM sodium phosphate buffer, pH 7.4, 150mM sodium chloride and 2mM EDTA at 37°C. (D) The percentage protection provided by each 14-3-3 ζ protein, at a 1:1 molar equivalence of 14-3-3 ζ :ADH.	45

Figure 3.7: The chaperone activity of (A) WT (B) V176D and (C) L216, 220, 227D 14-3-3 ζ against the amorphous aggregation of alcohol dehydrogenase at physiological pH.(D) The percent protection provided by each 14-3-3 ζ protein at a 1:1 molar equivalence of 14-3-3 ζ :ADH.	47
Figure 3.8: The crystal structure of 14-3-3 ζ showing the close proximity between Val176 and Arg56, with a distance of 6.8Å.	49
Figure 4.1: The crystal structure (side and bottom views) of 14-3-3 ζ (16) showing the location of the potential salt bridging residues D21 (red) and E89 (blue) and phosphorylatable residue, S58 (yellow) in the dimer interface.	53
Figure 4.2: Native-PAGE analysis of the mutated 14-3-3 ζ proteins visualised by Coomassie blue staining.	55
Figure 4.3: The far-UV circular dichroism spectra of WT and (A) D21N, (B) E89Q, (C) S58D, (D) D21N/E89Q/S58A and (E) D21N/E89Q/S58D 14-3-3 ζ	57
Figure 4.4: The intrinsic tryptophan fluorescence profiles of WT compared with (A) D21N, (B) E89Q, (C) S58D, (D) D21N/E89Q/S58A and (E) D21N/E89Q/S58D 14-3-3 ζ , at 7.2 μ M60	
Figure 4.5: The intrinsic tryptophan fluorescence spectra of WT compared with (A) D21N, (B) E89Q, (C) S58D, D) D21NE89QS58A and (E) D21NE89QS58D 14-3-3 ζ , at 1.4 μ M.....	63
Figure 4.6: The thermostability profiles of WT compared with (A) D21N, (B) E89Q, (C) S58D, (D) D21N/E89Q/S58A and (E) D21N/E89Q/S58A 14-3-3 ζ	65
Figure 4.7: The titration of bis-ANS with WT (black), D21N (green), E89Q (blue), S58D (red), D21N/E89Q/S58A (orange) and D21N/E89Q/S58D (purple) 14-3-3 ζ proteins	67
Figure 4.8: (A) The chemical structure of CTAB (B) The phosphorylation of WT, D21N, E89Q and S58D 14-3-3 ζ proteins by protein kinase A in the presence and absence of CTAB, and visualised by autoradiography.....	70
Figure 4.9: The chaperone action of (A) WT, (B) D21N, (C) E89Q and (D) S58D 14-3-3 ζ against the amorphous aggregation of ADH at 42°C, and pH 7.4. The percent protection afforded against the amorphous aggregation of ADH at a 1:1 (E) and 1:2 (F) molar equivalence of ADH: 14-3-3 ζ , after 100mins.....	72

Figure 4.10: The chaperone action of (A) WT, (B) D21N/E89Q/S58A and (C) D21N/E89Q/S58D 14-3-3 ζ against the amorphous aggregation of ADH at 42°C. The percent protection afforded against the amorphous aggregation of ADH at a 1:1 (D) and 1:2 (E) molar equivalence after 150mins	73
Figure 4.11: The chaperone action of (A) WT, (B) E89Q, (C) D21N/E89Q/S58A and (D) D21N/E89Q/S58D 14-3-3 ζ against the amorphous aggregation of reduced insulin. The percent protection afforded against the amorphous aggregation of insulin at a 1:1 (E) and 1:2 (F) molar equivalence after 80mins.	76
Figure 4.12: Monitoring the intrinsic fluorescence of the (A) WT and (B) D21N/E89Q/S58A 14-3-3 ζ whilst interacting with the amorphously aggregating reduced insulin (2mg/mL) at 0 (black) and 50mins (red) at a 1:2 molar ratio of reduced insulin:14-3-3 ζ . (E) The change in fluorescence intensity with time, of reduced insulin and WT 14-3-3 (black), reduced insulin and D21N/E89Q/S58A 14-3-3 ζ (red) and reduced insulin alone (green) at 345nm and 350nm for each protein respectively	79
Figure 4.13: The arrangement of R18 (blue) and Y82 (green) within the dimer interface.....	82
Figure 5.1: The cross-linking of 14-3-3 ζ proteins by glutaraldehyde; (A) Cross-linking of WT, D21N, E89Q and S58D 14-3-3 ζ by glutaraldehyde (0.001-0.005%) was analysed by immuno-blotting for 14-3-3 after SDS-PAGE.....	88
Figure 5.2: The principle of sedimentation velocity experiments showing how sedimentation of a protein produces a concentration boundary	89
Figure 5.3: (A) The continuous sedimentation coefficient ($c(s)$) distribution of WT 14-3-3 ζ at 20°C plotted as a function of sedimentation coefficient ($s_{20,w}$).....	91
Figure 5.4: The continuous sedimentation coefficient ($c(s)$) distribution of WT (black), D21N (green), E89Q (blue), S58D (red) and D21N/E89Q/S58A (orange) 14-3-3 ζ were plotted as a function of sedimentation coefficient ($s_{20,w}$) at 0.27mg/mL and 20°C.....	92
Figure 5.5: The continuous sedimentation coefficient ($c(s)$) distribution of WT (black), D21N (green), E89Q (blue), S58D (red) and D21N/E89Q/S58A (orange) 14-3-3 ζ at 0.09mg/mL and 20°C.....	93

Figure 5.6: The continuous sedimentation coefficient ($c(s)$) distribution of WT 14-3-3 ζ at 4°C (dashed line), 20°C (solid line) and 37°C (dotted line) at 0.09mg/mL	95
Figure 5.7: The hypothesised mechanism of the chaperone action of 14-3-3 ζ against amorphously aggregating target proteins, whereby under stress conditions, 14-3-3 ζ dissociates from the dimer, in order to interact with and stabilise aggregating target proteins. The native form of the protein can be recovered with the aid of other chaperone proteins (Hsp70) coupled with ATP hydrolysis	99
Figure 6.1: The chemical structure of sphingosine, the physiological lipid that disrupt the dimer interface of WT 14-3-3 ζ	101
Figure 6.2: The phosphorylation of WT 14-3-3 ζ by PKA in the presence and absence of various concentrations of #41.14	103
Figure 6.3: (A) The fluorescence spectrum of sphingosine mimic, #41.14 alone (14.4 μ M) upon excitation at 295nm, with the emission acquired between 300 and 600nm, in sodium phosphate buffer, pH 7.4, and 37°C. (B) The intrinsic fluorescence profile of WT 14-3-3 ζ (1.4 μ M) in the presence and absence of the small molecule, #41.14	104
Figure 6.4: The thermostability profile of WT 14-3-3 ζ (7.2 μ M) in the presence and absence of #41.14 (14.4 μ M), obtained by monitoring the intrinsic tryptophan fluorescence emission at 345nm between 37-80°C.....	105
Figure 6.5: The titration of bis-ANS (μ M) with WT 14-3-3 ζ (1.4 μ M) in the presence and absence of #41.14.....	106
Figure 6.6: The interaction of bis-ANS (μ M) with sphingosine mimic, #41.14 (2.8 μ M). ...	108
Figure 6.7: The chaperone action of WT 14-3-3 ζ (14 μ M) in the (A) absence and (B) presence of the small molecule #41.14 (28 μ M) against the amorphous aggregation of ADH (14 μ M), in sodium phosphate buffer, pH 7.4, at 37°C. (C) The percent protection afforded by WT 14-3-3 ζ in the absence and presence of small molecule #41.14, against the amorphous aggregation of ADH at a 1:1 molar ratio of ADH: 14-3-3 ζ	110
Figure 7.1: The scattering length density of protonated (blue) and deuterated (red) proteins and water (black), as a function of the D ₂ O/H ₂ O ratio of the solvent	116

Figure 7.2: The scattering intensities and pair distance distribution plots for different geometric bodies	117
Figure 7.3: The chaperone activity of 14-3-3 ζ against the amorphous aggregation of ADH (28 μ M) upon addition of EDTA (2mM) at (A) 42 $^{\circ}$ C, (B) 37 $^{\circ}$ C and (C) 33 $^{\circ}$ C. (D) The aggregation of ADH at 33 $^{\circ}$ C, 37 $^{\circ}$ C and 42 $^{\circ}$ C (E) The percent protection of WT 14-3-3 ζ at a 1:2 molar equivalence of ADH:14-3-3 at 42 $^{\circ}$ C, 37 $^{\circ}$ C and 33 $^{\circ}$ C.....	119
Figure 7.4: The P(r) distributions of (A) native ADH and (B) 14-3-3 ζ . The ab initio modelling of the scattering data overlaid with the crystal structures of (C) native ADH and (D) 14-3-3 ζ as determined using the Dammin software from the ATSAS suite	121
Figure 7.5: (A) The P(r) distributions of amorphously aggregating ADH with time. (B) The scattering profiles of aggregating ADH with time, showing a reduction in the overall intensity (inset) of the scattering at low q with time.	122
Figure 7.6: The P(r) distribution of aggregating ADH (28 μ M) in the presence (black) and absence (blue) of 14-3-3 ζ (at a 3x molar equivalence) at 240 minutes.	123
Figure 7.7: (A) The circular dichroism spectra of hydrogenated 14-3-3 ζ (black) compared with deuterated 14-3-3 ζ (red) between 195 and 250nm represented as the average of three accumulations. (B) The intrinsic fluorescence spectrum of hydrogenated 14-3-3 ζ (black) compared with deuterated 14-3-3 (red) after excitation at 295nm with the emission acquired between 300 and 400nm. (C) The thermostability profile of hydrogenated 14-3-3 ζ (black) compared with deuterated 14-3-3 ζ (red) obtained by monitoring the intrinsic tryptophan fluorescence at 340nm between 37-80 $^{\circ}$ C.....	126
Figure 7.8: The percent protection provided by h14-3-3 ζ (grey) and d14-3-3 ζ (black) against the amorphous aggregation of ADH (28 μ M) at a 1:1 molar equivalence of ADH: 14-3-3 ζ at 42 $^{\circ}$ C in 50mM sodium phosphate buffer, pH 7.4	127
Figure 7.9: (A) The pair distance distribution (p(r)) of native ADH at 100% D ₂ O. (B) The low resolution ab initio model of native ADH tetramer overlaid with the X-ray crystal structure.....	129

Figure 7.10: (A) The pair-distance distributions of deuterated 14-3-3 ζ at 40% D₂O. (B) The X-ray crystal structure utilised in the Oligomer analysis, showing the likely orientation of the two 14-3-3 dimers to form a tetrameric structure. Each dimer is coloured differently 130

Figure 7.11: (A) The scattering profiles of aggregating ADH with time, showing the decrease in scattering intensity as ADH precipitates out of solution. (B) The pair-distance distribution of aggregating alcohol dehydrogenase with time at 100% D₂O 133

Figure 7.12: The p(r) distributions of the protein mixture at (A) 100% and (B) 40% D₂O, representing ADH and 14-3-3 ζ respectively, prior to the addition of EDTA to the mixture of both proteins (at a 1:1 molar ratio). 134

Figure 7.13: The p(r) distributions of destabilised ADH in the presence of the molecular chaperone 14-3-3 ζ at a 1:1 (A) and a 1:2 (B) molar ratio of ADH:14-3-3 ζ at 100% D₂O with time. 135

Figure 7.14: The low resolution model of ADH at 100% D₂O, in the presence of a molar equivalence of 14-3-3 ζ . The crystal structure of native ADH is for the comparison to show the overall elongation of the intermediately folded state of ADH..... 136

Figure 7.15: The p(r) distributions for the 14-3-3 ζ in the presence of destabilised ADH at a (A) 1:1 and (B) 1:2 molar ratio of ADH:14-3-3 ζ at 40% D₂O. (C) Summary of R_g values and volume % of dimer and tetramer from Oligomer analysis of the 14-3-3 ζ data at 40% D₂O in the presence of ADH..... 137

Figure 7.16: Modelling (obtained using the MONSA component program from the ATSAS suite), showing the most likely interaction between 14-3-3 ζ (green) and the intermediately folded state of ADH (yellow), with the X-ray crystal structure of 14-3-3 ζ (red) overlaid showing the amphipathic binding groove 139

Figure 7.17: Modelling (obtained using the MONSA component program from the ATSAS suite), showing the most likely interaction between 14-3-3 ζ (green) and the intermediately folded state of ADH (yellow), with the X-ray crystal structure of 14-3-3 ζ (red) overlaid showing the dimer interface interaction regions joined by an aperture 140

Figure 7.18: The alignment of the helices in the dimer interface of 14-3-3 ζ highlighting the two interaction regions separated by an aperture..... 145

Figure 8.1: The crystal structure of a mutant 14-3-3 ζ protein (A16C/S58C) highlighting the disulphide bridges (yellow) across the dimer interface to generate a protein which cannot dissociate from the dimer.....	153
Figure A.1: The far-UV CD spectra of a helical protein myoglobin (red), beta sheet proteins concanavalin A (blue) and beta-lactoglobulin (cyan) and a polyproline rich protein, collagen (orange).....	157
Figure A.2: (A) The fluorescence emission spectra of free Trp (dashed line) and 14-3-3 ζ (solid line) when excited at 295nm, showing the resultant blue shift and decrease in intensity, upon burial of the Trp residues in the protein in addition to the quenching effects of the adjacent amino acids. (B) The locality of the two tryptophan residues in the 14-3-3 ζ protein are, Trp59 (in helix 3) and Trp228 (helix 9) as indicated.....	159
Figure A.3: The π - π stacking of W228 (red) and Y179 (blue) of 14-3-3 ζ is equivalent to 14-3-3 γ . This interaction potentially quenches the fluorescence of W228.....	160
Figure A.4: The chemical structure of Bis-ANS.....	161
Figure B.1: (A) The FPLC trace of WT 14-3-3 ζ (previously purified by Ni-affinity chromatography) after purification by size exclusion chromatography showing one protein peak. (B) SDS-PAGE analysis of the fractions collected via FPLC, confirming that the protein peak after size exclusion chromatography is WT 14-3-3 ζ with purity greater than 95%.....	163

List of tables

Table 1.1: Human neurological diseases associated with the formation of toxic proteinaceous deposits (adapted from Taylor (29), and Chiti and Dobson (31)), and the 14-3-3 isoforms associated with each disease (4,13).	12
Table 2.1: The oligonucleotides utilised to generate the necessary mutation in the 14-3-3 gene, with the mutated bases highlighted in bold. Any restriction sites are highlighted by underlining.	24
Table 2.2: The molecular weight (in Daltons) of the 14-3-3 ζ proteins, for the calculation of protein concentration.	26
Table 4.1: The maximum emission wavelengths of WT and the mutated 14-3-3 ζ proteins at 7.2 μ M, in 20mM phosphate buffer, pH7.4, and 37°C	58
Table 4.2: The maximum fluorescence wavelength obtained from the intrinsic fluorescence spectra of the WT and mutated 14-3-3 ζ proteins.	61
Table 4.3: The calculated melting temperatures ($^{\circ}$ C) of the 14-3-3 ζ proteins	64
Table 4.4: The percent protection afforded by the 14-3-3 ζ proteins against the amorphous aggregation of ADH at a 1:1 and a 1:2 molar equivalence of ADH: 14-3-3 ζ	71
Table 4.5: The percent protection afforded by the 14-3-3 ζ proteins against the amorphous aggregation of reduced insulin at a 1:1 and 1:2 molar ratio.	75
Table 5.1: The standardised sedimentation coefficients ($S_{20,w}$) of WT, D21N, E89Q, S58D and D21N/E89Q/S58A 14-3-3 ζ at 0.27mg/mL and 0.09mg/mL, with the difference between the concentrations ($\Delta S_{20,w}$) stated.	94
Table 5.2: The standardised sedimentation coefficients ($S_{20,w}$) determined for WT, D21N, E89Q, S58D and D21N/E89Q/S58A 14-3-3 ζ proteins at 4, 20 and 37°C and 0.09mg/mL. ...	96

Table 7.1: A table showing the radius of gyration (R_g) values of native and unfolding ADH in 100% D₂O over time, as estimated by Guinier analysis. 131